Matthew Bryan Potts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew Bryan Potts has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Babak S. Jahromi
Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL (B.J.).
20 shared publications Babak S. Jahromi
Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
12 shared publications- Sameer A. Ansari
Department of Radiology, Northwestern University, Feinberg School of Medicine
12 shared publications - Pedram Golnari
Case Western Reserve University School of Medicine
10 shared publications Ali Shaibani
Departments of Neurological Surgery and
8 shared publications- Ali Shaibani
Department of Radiology, Ann and Robert H. Lurie Children’s Hospital of Chicago, IL (A.S.).
8 shared publications
Latest Publications
- 11 March 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Modeling interhospital stroke transfers for endovascular treatment in the four largest cities in the USA
Background Interhospital transfers of stroke patients to higher levels of care for endovascular treatment (EVT) are common. Optimizing transfer times may help improve overall reperfusion times. We sought to model and compare the ground travel times for health system-affiliated and nearest EVT-capable stroke center transfers and examine associated factors in the four largest cities in the USA: New York City (NYC), Los Angeles (LA), Chicago, and Houston. Methods We identified EVT-capable centers (defined as comprehensive, thrombectomy-capable, and primary plus stroke centers) and their health system-affiliated hospitals for each city. For each affiliated hospital, we used a Monte Carlo simulation to model ambulance travel times to its system EVT-capable center as well as the nearest EVT-capable center. We subsequently analyzed hospital service area variables associated with prolonged (extra travel time to affiliated hospital >20 min) transfers. Results The total travel time (mean (SD), min) to an affiliated versus nearest EVT-capable center was 29.9 (10.2) versus 14.4 (2.0) (PConclusion This study characterized theoretical stroke transfer networks in the four largest US cities and showed that affiliated-hospital system transfers may increase overall transfer times compared with transferring to the nearest EVT-capable center.
- 11 March 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Modeling interhospital stroke transfers for endovascular treatment in the four largest cities in the USA
Background Interhospital transfers of stroke patients to higher levels of care for endovascular treatment (EVT) are common. Optimizing transfer times may help improve overall reperfusion times. We sought to model and compare the ground travel times for health system-affiliated and nearest EVT-capable stroke center transfers and examine associated factors in the four largest cities in the USA: New York City (NYC), Los Angeles (LA), Chicago, and Houston. Methods We identified EVT-capable centers (defined as comprehensive, thrombectomy-capable, and primary plus stroke centers) and their health system-affiliated hospitals for each city. For each affiliated hospital, we used a Monte Carlo simulation to model ambulance travel times to its system EVT-capable center as well as the nearest EVT-capable center. We subsequently analyzed hospital service area variables associated with prolonged (extra travel time to affiliated hospital >20 min) transfers. Results The total travel time (mean (SD), min) to an affiliated versus nearest EVT-capable center was 29.9 (10.2) versus 14.4 (2.0) (PConclusion This study characterized theoretical stroke transfer networks in the four largest US cities and showed that affiliated-hospital system transfers may increase overall transfer times compared with transferring to the nearest EVT-capable center.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 3084-3089
Biomarkers of Thromboelastography Platelet Mapping Predict Hematoma Expansion After Spontaneous Intracerebral Hemorrhage
BACKGROUND: Hematoma expansion (HE) is a preventable cause of disability and death in patients with acute intracerebral hemorrhage (ICH). Platelet activity is essential for coagulation, and antiplatelet medications (eg, aspirin, clopidogrel) increase HE risk. General markers of platelet activity are associated with later HE, but specific biomarkers of platelet activity could enhance our understanding. We hypothesized that hemostatic biomarkers of platelet activity would correlate with later HE. METHODS: We conducted a tri-center observational cohort study of spontaneous ICH patients with multiple imaging scans for HE calculation. The thromboelastography 6s Platelet Mapping assay assessed platelet activity with 3 biomarkers: (1) adenosine diphosphate receptor-induced platelet activation, (2) platelet-fibrin network clot strength measured by heparinized kaolin with heparinase, and (3) fibrinogen-only clot strength measured by activator F (ActF). Spearman rank measured the correlation between HE and platelet activity. A linear regression model predicted HE from ActF. We tested whether the relationship between ActF and HE interacted with pre-ICH antiplatelet medication. RESULTS: Thirty-five patients were included. Eleven (35.48%) took pre-ICH antiplatelet medication. Heparinized kaolin with heparinase negatively correlated with HE ( ρ =−0.34, P =0.02), indicating that stronger platelet-fibrin clots were associated with less subsequent HE. ActF’s association with HE depended on pre-ICH antiplatelet medication use (interaction P =0.005). More ActF (fibrinogen) was associated with less HE in patients who did not take pre-ICH antiplatelet medication. CONCLUSIONS: Hemostatic biomarkers from the thromboelastography 6s Platelet Mapping assay predicted subsequent HE and may aid in determining neurosurgical need. Strengthening platelet-mediated coagulation may be a target for reducing HE and improving ICH outcomes.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 3084-3089
Biomarkers of Thromboelastography Platelet Mapping Predict Hematoma Expansion After Spontaneous Intracerebral Hemorrhage
BACKGROUND: Hematoma expansion (HE) is a preventable cause of disability and death in patients with acute intracerebral hemorrhage (ICH). Platelet activity is essential for coagulation, and antiplatelet medications (eg, aspirin, clopidogrel) increase HE risk. General markers of platelet activity are associated with later HE, but specific biomarkers of platelet activity could enhance our understanding. We hypothesized that hemostatic biomarkers of platelet activity would correlate with later HE. METHODS: We conducted a tri-center observational cohort study of spontaneous ICH patients with multiple imaging scans for HE calculation. The thromboelastography 6s Platelet Mapping assay assessed platelet activity with 3 biomarkers: (1) adenosine diphosphate receptor-induced platelet activation, (2) platelet-fibrin network clot strength measured by heparinized kaolin with heparinase, and (3) fibrinogen-only clot strength measured by activator F (ActF). Spearman rank measured the correlation between HE and platelet activity. A linear regression model predicted HE from ActF. We tested whether the relationship between ActF and HE interacted with pre-ICH antiplatelet medication. RESULTS: Thirty-five patients were included. Eleven (35.48%) took pre-ICH antiplatelet medication. Heparinized kaolin with heparinase negatively correlated with HE ( ρ =−0.34, P =0.02), indicating that stronger platelet-fibrin clots were associated with less subsequent HE. ActF’s association with HE depended on pre-ICH antiplatelet medication use (interaction P =0.005). More ActF (fibrinogen) was associated with less HE in patients who did not take pre-ICH antiplatelet medication. CONCLUSIONS: Hemostatic biomarkers from the thromboelastography 6s Platelet Mapping assay predicted subsequent HE and may aid in determining neurosurgical need. Strengthening platelet-mediated coagulation may be a target for reducing HE and improving ICH outcomes.
- 18 February 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (4) , e101
In Reply: Safety of Postembolization Antithrombotic Therapy After Middle Meningeal Artery Embolization
- 18 February 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (4) , e101
In Reply: Safety of Postembolization Antithrombotic Therapy After Middle Meningeal Artery Embolization
- 26 November 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 248, 108664
Bilateral middle meningeal artery embolization for the treatment of bilateral chronic subdural hematoma
- 26 November 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 248, 108664
Bilateral middle meningeal artery embolization for the treatment of bilateral chronic subdural hematoma
- 25 November 2024
- Published by Elsevier in World Neurosurgery
- Vol. 193, 1145-1164
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Bibliometric Analysis
- 25 November 2024
- Published by Elsevier in World Neurosurgery
- Vol. 193, 1145-1164
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Bibliometric Analysis
- 2 November 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (8) , 848-858
Neuroanatomy of the vertebrobasilar perforators: implications for aneurysm treatment
The anatomy of vertebrobasilar perforators has been widely studied in human cadavers, with most reports found in the neurosurgical literature. These arterial perforators are extremely hard to visualize consistently with traditional two-dimensional digital subtraction angiography, but are reliably visible with cross sectional cone beam CT techniques. A clear understanding of this specific neurovascular anatomy and pathology is essential for informed treatment decisions. This review analyzes the anatomy of vertebrobasilar perforators with a focus on practical implications for aneurysm treatment, particularly flow diversion.
- 2 November 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (8) , 848-858
Neuroanatomy of the vertebrobasilar perforators: implications for aneurysm treatment
The anatomy of vertebrobasilar perforators has been widely studied in human cadavers, with most reports found in the neurosurgical literature. These arterial perforators are extremely hard to visualize consistently with traditional two-dimensional digital subtraction angiography, but are reliably visible with cross sectional cone beam CT techniques. A clear understanding of this specific neurovascular anatomy and pathology is essential for informed treatment decisions. This review analyzes the anatomy of vertebrobasilar perforators with a focus on practical implications for aneurysm treatment, particularly flow diversion.
- 28 October 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (4) , 734-743
Laparoscopic-Assisted Peritoneal Access in Ventriculoperitoneal Shunt Placement: Systematic Review and Meta-Analysis
BACKGROUND AND OBJECTIVES: The most common treatment of hydrocephalus is ventriculoperitoneal (VP) shunting. Peritoneal access is commonly conducted through an open laparotomy, but laparoscopic peritoneal access is gaining popularity. Many studies have reported the benefits of minimally invasive laparoscopic peritoneal access, but there is no consensus on its use. We conducted a systematic review and meta-analysis to compare open laparotomy vs laparoscopic peritoneal access in VP shunting. METHODS: A systematic search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using 3 databases. Twelve studies included only adults, 3 included only pediatric patients, and 3 included both adults and pediatric patients. RESULTS: Compared with open laparotomy, laparoscopic peritoneal access was associated with a reduction in distal shunt failure (6.1% vs 2.2%, P = .01), operative time (69.4 vs 56.3 minutes, P < .001), and length of stay (LOS) (9.6 vs 7.3 days, P < .001). There were no differences in proximal shunt failure, total shunt failure, intraoperative complications, or infection rate. In the pediatric population, laparoscopic access was associated with a reduced LOS (7.8 vs 5.9 days, P < .001). Heterogeneity was high but explained by the varying study populations and techniques. CONCLUSION: Laparoscopic peritoneal access for VP shunt insertion is associated with improved outcomes, including reduced distal shunt failure, reduced operative time, and reduced hospital LOS, when compared with open laparotomy and should be considered for shunt insertion. Additional studies are necessary to further determine the benefit of laparoscopic access, especially in the pediatric population.
- 28 October 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (4) , 734-743
Laparoscopic-Assisted Peritoneal Access in Ventriculoperitoneal Shunt Placement: Systematic Review and Meta-Analysis
BACKGROUND AND OBJECTIVES: The most common treatment of hydrocephalus is ventriculoperitoneal (VP) shunting. Peritoneal access is commonly conducted through an open laparotomy, but laparoscopic peritoneal access is gaining popularity. Many studies have reported the benefits of minimally invasive laparoscopic peritoneal access, but there is no consensus on its use. We conducted a systematic review and meta-analysis to compare open laparotomy vs laparoscopic peritoneal access in VP shunting. METHODS: A systematic search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using 3 databases. Twelve studies included only adults, 3 included only pediatric patients, and 3 included both adults and pediatric patients. RESULTS: Compared with open laparotomy, laparoscopic peritoneal access was associated with a reduction in distal shunt failure (6.1% vs 2.2%, P = .01), operative time (69.4 vs 56.3 minutes, P < .001), and length of stay (LOS) (9.6 vs 7.3 days, P < .001). There were no differences in proximal shunt failure, total shunt failure, intraoperative complications, or infection rate. In the pediatric population, laparoscopic access was associated with a reduced LOS (7.8 vs 5.9 days, P < .001). Heterogeneity was high but explained by the varying study populations and techniques. CONCLUSION: Laparoscopic peritoneal access for VP shunt insertion is associated with improved outcomes, including reduced distal shunt failure, reduced operative time, and reduced hospital LOS, when compared with open laparotomy and should be considered for shunt insertion. Additional studies are necessary to further determine the benefit of laparoscopic access, especially in the pediatric population.
- 20 September 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (4) , 901-907
Safety of Postembolization Antithrombotic Therapy After Middle Meningeal Artery Embolization
BACKGROUND AND OBJECTIVES: Middle meningeal artery embolization (MMAE) for the management of chronic subdural hematoma (cSDH) has been suggested as a preferred treatment in patients where reinitiating antithrombotic (AT) therapy is necessary. In this study, we evaluate whether reinitiating AT therapy before cSDH resolution after MMAE affects radiographic and clinical resolution. METHODS: This is a retrospective study of patients who underwent MMAE at our institution between 2018 and 2024. Clinical and radiographic findings were analyzed with standard statistical approaches. Kaplan-Meier curves for nonresolution compared AT and no-AT groups and compared AT resumption before and after 30 days after surgery. RESULTS: In 111 MMAE procedures, the median age was 73 years, 27.9% were female, and 80.6% were White. The median follow-up was 5.1 months. Forty-six patients (41.4%) demonstrated complete resolution of their cSDH. Eleven patients (9.9%) had reoperation after MMAE. The median cSDH depth was 14.0 mm, and the median midline shift was 3.0 mm. Thirty-two patients (28.8%) resumed AT before resolution. The median time to resumption was 35.5 days. Patients in the AT group were less likely to have radiographic resolution (21.9% vs 49.4%, odds ratios = 0.2872, 95% CI = 0.1113-0.7404, P = .0103) but comparable rates of reoperation and residual symptomatic presentations. Resumption of AT therapy before or after 30 days from surgery had no effects on outcome measures on univariate analysis. Major outcomes were similar between patients receiving antiplatelet-only or anticoagulant-only medications. CONCLUSION: Reinitiating AT therapy before cSDH resolution was associated with decreased rates of resolution, but comparable rates of reoperation and residual symptoms. Our results support the cautious reinitiation of AT therapy in patients requiring it after MMAE.
- 20 September 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (4) , 901-907
Safety of Postembolization Antithrombotic Therapy After Middle Meningeal Artery Embolization
BACKGROUND AND OBJECTIVES: Middle meningeal artery embolization (MMAE) for the management of chronic subdural hematoma (cSDH) has been suggested as a preferred treatment in patients where reinitiating antithrombotic (AT) therapy is necessary. In this study, we evaluate whether reinitiating AT therapy before cSDH resolution after MMAE affects radiographic and clinical resolution. METHODS: This is a retrospective study of patients who underwent MMAE at our institution between 2018 and 2024. Clinical and radiographic findings were analyzed with standard statistical approaches. Kaplan-Meier curves for nonresolution compared AT and no-AT groups and compared AT resumption before and after 30 days after surgery. RESULTS: In 111 MMAE procedures, the median age was 73 years, 27.9% were female, and 80.6% were White. The median follow-up was 5.1 months. Forty-six patients (41.4%) demonstrated complete resolution of their cSDH. Eleven patients (9.9%) had reoperation after MMAE. The median cSDH depth was 14.0 mm, and the median midline shift was 3.0 mm. Thirty-two patients (28.8%) resumed AT before resolution. The median time to resumption was 35.5 days. Patients in the AT group were less likely to have radiographic resolution (21.9% vs 49.4%, odds ratios = 0.2872, 95% CI = 0.1113-0.7404, P = .0103) but comparable rates of reoperation and residual symptomatic presentations. Resumption of AT therapy before or after 30 days from surgery had no effects on outcome measures on univariate analysis. Major outcomes were similar between patients receiving antiplatelet-only or anticoagulant-only medications. CONCLUSION: Reinitiating AT therapy before cSDH resolution was associated with decreased rates of resolution, but comparable rates of reoperation and residual symptoms. Our results support the cautious reinitiation of AT therapy in patients requiring it after MMAE.